文献速递MDS 与骨髓增殖性肿瘤

骨髓纤维化中的细胞因子产生对JAK-STAT、MAP激酶和NFκB信号通路表现出差异性反应

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.
PubMed 文献 · Leukemia · 2019-02-04

研究采用质谱流式技术检测骨髓纤维化(MF)患者血浆及血液细胞体外细胞因子产生,发现鲁索替尼治疗后血浆细胞因子仍显著异常,15种细胞因子中14种组成性过表达且主要来源于单核细胞,多数对TPO、TLR配体和/或TNF表现出体外超敏反应,其中部分对鲁索替尼敏感性低,但所有TPO/TLR/TNF敏感性细胞因子均对NFκB和/或MAP激酶信号通路药理学抑制敏感。

要点

  • 鲁索替尼治疗后MF患者血浆细胞因子仍显著异常,提示JAK2抑制未能纠正异常细胞因子产生。
  • MF患者样本中15种细胞因子有14种组成性过表达,多数细胞因子的主要来源为单核细胞。
  • 多数升高的细胞因子对TPO、TLR配体和/或TNF体外超敏,其中部分对鲁索替尼敏感性低。

核心结论

  • NFκB和MAP激酶信号通路维持MF中的细胞因子过表达。
  • 抑制这些通路可能为控制MF炎症病理生理提供最优策略。

研究设计与样本

  • 研究采用质谱流式技术检测MF患者血浆及MF血液细胞体外细胞因子产生。

主要发现

  • 鲁索替尼治疗后血浆细胞因子仍显著异常。
  • MF患者样本中15种细胞因子有14种组成性过表达,多数细胞因子的主要来源为单核细胞。
  • 多数升高的细胞因子对TPO、TLR配体和/或TNF表现出体外超敏反应。
  • 包括TNF、IL-6、IL-8、IL-10在内的部分细胞因子对鲁索替尼敏感性低。
  • 所有TPO/TLR/TNF敏感性细胞因子均对NFκB和/或MAP激酶信号通路的药理学抑制敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The distinct clinical features of myelofibrosis (MF) have been attributed in part to dysregulated inflammatory cytokine production. Circulating cytokine levels are elevated in MF patients; a subset of which have been shown to be poor prognostic indicators. In this study, cytokine overproduction was examined in MF patient plasma and in MF blood cells ex vivo using mass cytometry. Plasma cytokines measured following treatment with ruxolitinib remained markedly abnormal, indicating that aberrant cytokine production persists despite therapeutic JAK2 inhibition. In MF patient samples, 14/15 cytokines measured by mass cytometry were found to be constitutively overproduced, with the principal cellular source for most cytokines being monocytes, implicating a non-cell-autonomous role for monocyte-derived cytokines impacting disease-propagating stem/progenitor cells in MF. The majority of cytokines elevated in MF exhibited ex vivo hypersensitivity to thrombopoietin (TPO), toll-like receptor (TLR) ligands, and/or tumor necrosis factor (TNF). A subset of this group (including TNF, IL-6, IL-8, IL-10) was minimally sensitive to ruxolitinib. All TPO/TLR/TNF-sensitive cytokines, however, were sensitive to pharmacologic inhibition of NFκB and/or MAP kinase signaling. These results indicate that NFκB and MAP kinase signaling maintain cytokine overproduction in MF, and that inhibition of these pathways may provide optimal control of inflammatory pathophysiology in MF.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fisher DAC, Miner CA, Engle EK, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 2019. PMID: 30718771. doi:10.1038/s41375-019-0379-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。